Aimmune Therapeutics (AIMT) Tops Q1 EPS by 15c

Aimmune Therapeutics (NASDAQ: AIMT) reported Q1 EPS of ($1.03), $0.15 better than the analyst estimate of ($1.18). Revenue for the quarter came in at $575 thousand versus the consensus estimate of $1.34 million.

“We have remained in close contact with allergists during the shelter-in-place, and their enthusiasm for initiating PALFORZIA therapy, as they begin to reopen their practices, remains as high as when it was approved in January,” said Jayson Dallas, M.D., President and Chief Executive Officer of Aimmune Therapeutics. “In addition, market research conducted among patient-caregivers suggests the demand for PALFORZIA has not changed. Our overall fundamentals and long-term prospects remain strong.”

For earnings history and earnings-related data on Aimmune Therapeutics (AIMT) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• John B. Sanfilippo & Son (JBSS) Misses Q4 EPS by 59c
• Lowe's slashes full-year sales outlook amid DIY spending pressure